Brokerages Set Bicara Therapeutics Inc. (NASDAQ:BCAX) PT at $30.27

Bicara Therapeutics Inc. (NASDAQ:BCAX) has been given a consensus recommendation of “Moderate Buy” by the fifteen research firms that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, three have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $30.2727.

Several research firms recently issued reports on BCAX. Morgan Stanley raised their target price on Bicara Therapeutics from $36.00 to $37.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 12th. The Goldman Sachs Group upped their price target on Bicara Therapeutics from $16.00 to $18.00 and gave the company a “neutral” rating in a research report on Tuesday, May 12th. Guggenheim initiated coverage on Bicara Therapeutics in a report on Monday, May 11th. They issued a “buy” rating and a $42.00 price objective for the company. Wall Street Zen upgraded Bicara Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, May 24th. Finally, Citizens Jmp reissued a “market outperform” rating and set a $31.00 target price on shares of Bicara Therapeutics in a research note on Tuesday, March 31st.

Bicara Therapeutics Price Performance

NASDAQ BCAX opened at $29.00 on Monday. Bicara Therapeutics has a 12-month low of $8.74 and a 12-month high of $29.90. The company has a 50-day simple moving average of $22.70 and a two-hundred day simple moving average of $19.70. The firm has a market cap of $1.91 billion, a price-to-earnings ratio of -10.43 and a beta of -0.81.

Bicara Therapeutics (NASDAQ:BCAX) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by ($0.21). Equities analysts expect that Bicara Therapeutics will post -3.48 earnings per share for the current fiscal year.

Insider Activity at Bicara Therapeutics

In other Bicara Therapeutics news, insider David Raben sold 5,500 shares of the business’s stock in a transaction on Monday, April 27th. The shares were sold at an average price of $22.88, for a total transaction of $125,840.00. Following the transaction, the insider directly owned 55,286 shares of the company’s stock, valued at approximately $1,264,943.68. The trade was a 9.05% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Ivan Hyep sold 9,200 shares of the company’s stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $20.42, for a total transaction of $187,864.00. Following the completion of the transaction, the chief financial officer owned 145,355 shares of the company’s stock, valued at $2,968,149.10. This trade represents a 5.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 63,900 shares of company stock worth $1,420,704. 13.80% of the stock is currently owned by insiders.

Institutional Trading of Bicara Therapeutics

Several large investors have recently bought and sold shares of the company. AQR Capital Management LLC purchased a new stake in Bicara Therapeutics in the first quarter worth $248,000. Woodline Partners LP lifted its position in Bicara Therapeutics by 26.5% during the first quarter. Woodline Partners LP now owns 348,690 shares of the company’s stock valued at $4,543,000 after buying an additional 72,998 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Bicara Therapeutics by 36.8% during the 2nd quarter. Geode Capital Management LLC now owns 672,485 shares of the company’s stock valued at $6,248,000 after buying an additional 180,833 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Bicara Therapeutics by 26.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 27,458 shares of the company’s stock valued at $255,000 after buying an additional 5,664 shares in the last quarter. Finally, Legal & General Group Plc grew its position in shares of Bicara Therapeutics by 64.1% in the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after buying an additional 1,233 shares during the period.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.